Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexza Pharmaceuticals has selected AZ-007 (Staccato zaleplon) for the treatment of insomnia as the next product candidate to move forward into active development, following an Alexza technology and portfolio review during the first half of 2010.
Subscribe to our email newsletter
Addicere Therapeutics, a wholly-owned subsidiary of Alexza, has been launched by the company to develop all applications of the Staccato technology for the pharmaceutical uses of nicotine.
Thomas King, president and CEO of Alexza, said: “As we started 2010, we deployed the majority of our efforts and resources on the pre-commercialisation activities for AZ-004. Over the course of the first six months, we received notification of our PDUFA date, completed our first commercialisation agreement and are continuing the work on commercial manufacturing scale-up for our lead program.
“We also completed a thorough analysis of our Staccato system-enabled pipeline of programs and new Staccato-based product candidates, in order to prioritise and select programs we could plan to self-fund and programs we could plan to develop through collaborations.
“We intend to capitalise on our internal resources to develop certain product candidates and to identify routes to utilise external resources to develop other product candidates.”